# A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

> **NCT00516191** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Liposomal Doxorubicin/Melphalan/Bortezomib

## Key facts

- **NCT ID:** NCT00516191
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-10
- **Primary completion:** 2010-10
- **Final completion:** 2010-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** low accrual
- **Last updated:** 2015-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00516191

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00516191, "A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00516191. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*